spacer
spacer

PDBsum entry 6b0v

Go to PDB code: 
Top Page protein ligands metals Protein-protein interface(s) links
Signaling protein PDB id
6b0v
Contents
Protein chains
167 a.a.
Ligands
C8G ×2
GDP ×2
Metals
_CA ×4
Waters ×435

References listed in PDB file
Key reference
Title The reactivity-Driven biochemical mechanism of covalent krasg12c inhibitors.
Authors R.Hansen, U.Peters, A.Babbar, Y.Chen, J.Feng, M.R.Janes, L.S.Li, P.Ren, Y.Liu, P.P.Zarrinkar.
Ref. Nat Struct Mol Biol, 2018, 25, 454-462. [DOI no: 10.1038/s41594-018-0061-5]
PubMed id 29760531
Abstract
Activating mutations in KRAS are among the most common tumor driver mutations. Until recently, KRAS had been considered undruggable with small molecules; the discovery of the covalent KRASG12C inhibitors ARS-853 and ARS-1620 has demonstrated that it is feasible to inhibit KRAS with high potency in cells and animals. Although the biological activity of these inhibitors has been described, the biochemical mechanism of how the compounds achieve potent inhibition remained incompletely understood. We now show that the activity of ARS-853 and ARS-1620 is primarily driven by KRAS-mediated catalysis of the chemical reaction with Cys12 in human KRASG12C, while the reversible binding affinity is weak, in the hundreds of micromolar or higher range. The mechanism resolves how an induced, shallow and dynamic pocket not expected to support high-affinity binding of small molecules can nevertheless be targeted with potent inhibitors and may be applicable to other targets conventionally considered undruggable.
PROCHECK
Go to PROCHECK summary
 Headers

 

spacer

spacer